A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 30 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2017 Status changed from not yet recruiting to recruiting.
- 30 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.